Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Biological therapy, such as cellular adoptive immunotherapy using autologous
lymphocytes, may stimulate the immune system in different ways and stop tumor cells from
growing. Aldesleukin may stimulate the lymphocytes to kill tumor cells. Giving
cyclophosphamide together with autologous lymphocytes and aldesleukin may be an effective
treatment for metastatic melanoma.
PURPOSE: This phase I/II trial is studying the side effects of giving cyclophosphamide
together with autologous lymphocytes and aldesleukin and to see how well it works in treating
patients with metastatic melanoma.